Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib maintenance after short-cycle first-line platinum chemotherapy in HRD-positive advanced ovarian cancer
ChiCTR2300069060Phase 2Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fluzoparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 cohorts), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Progression-free survival rate at 12 months. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
fluzoparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2300069060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069060.